Our findings corroborate the inhibition of oncogenic RTK signaling elicited by ganetespib in ErbB2+ breast cancer cells41, which further supports the multi-faceted anti-cancer potential of ganetespib. This evidence concerns the gene ERBB2 and breast carcinoma.